Strategies for Biotech Companies to Scale Up Commercially through Effective Project and Risk Management

Varun Choudhary

Authors

Varun Choudhary Independent Researcher, 02143, Massachusetts

Keywords:

biotechnology, risk management, project management, scale-up, case studies, sustainability, ethical issues, environmental concerns, and social responsibility

Abstract

Growing biotechnology operations provide potential and problems for businesses across a range of industries, including industry, healthcare, and agriculture. With a focus on efficient project and risk management, this thorough review examines approaches, factors, and implications for commercial scale-up in biotech enterprises. In order to effectively navigate the intricacies of biotech scale-up, align objectives, proactively identify and mitigate risks, optimize resource allocation, and stimulate stakeholder participation and communication, it is imperative that project and risk management methodologies be integrated. Case studies provide best practices and lessons learned from successful commercial scale-up initiatives in the manufacturing of cell therapies, agricultural biotechnology, and biopharmaceuticals. Advances in precision medicine, synthetic biology, digitalization, omics technologies, sophisticated therapeutics, bioprocessing breakthroughs, and international partnerships are some of the future trends and prospects in biotech scale-up. With an emphasis on resource efficiency, renewable energy, waste reduction, green chemistry, biodiversity protection, and life cycle assessment, sustainability and environmental issues are critical to the biotech industry's scale-up. The ethical and social ramifications of biotech scale-up include questions of genetic engineering and manipulation, data ownership and intellectual property, privacy and informed permission, access and equity, dual-use research and biosecurity, environmental sustainability, and social responsibility. Biotech businesses can optimize the advantages of scale-up initiatives while avoiding risks and guaranteeing good societal effect by taking these factors into account and adopting responsible stewardship practices.

References

Decker, E.L. and Reski, R. (2008) Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess Biosyst. Eng. 31, 3–9. Doi: 10.1007/s00449-007-0151-y.

Dunmore, C. (2013) Monsanto to grow European seed business after GMO pullout. Reuters Markets, 18thJuly,http://web.archive.org/web/20140219045926/http://www.reuters.com/article/2013/07/18/monsanto-europe-id USL6N0FO3TB20130718.

Hokusan Co. Ltd. (2013) Interberry alpha product page (in Japanese): http:// web.archive.org/web/20150210081807/http://hokusan-kk.jp/info/index. Html.

P. Xu, C. Clark, T. Ryder, C. Sparks, J. Zhou, M. Wang, R. Russel, C. Scott, Biotechnol. Prog. 2017, 33, 478.

Amanullah, J. M. Otero, M. Mikola, A. Hsu, J. Zhang, J. Aunins, H. B. Schreyer, J. A. Hope, A. P. Russo, Biotechnol. Bioeng. 2010, 106, 57.

Chen, R. Chitta, D. Chang, A. Amanullah, Biotechnol. Bioeng. 2009, 102, 48. [24] S. R. Warr, Methods Mol. Biol. 2014, 1104, 149.

M. De Jesus, P. Girard, M. Bourgeois, G. Baumgartner, B. Jacko, H. Amstutz, F. M. Wurm, Biochem. Eng. J. 2004, 17, 217.

M. Gomez, M. Ambhaikar, L. Zhang, C. J. Huang, Biotechnol. Prog. 2017, 33, 490. [28] N. Matsunaga, K. Kano, Y. Maki, T. Dobashi, J. Biosci. Bioeng. 2009, 106, 412.

S. Xu, L. Hoshan, R. Jiang, B. Gupta, E. Brodean, K. O’Neill, T. C. Seamans, J. Bowers, H. Chen, Biotechnol. Prog. 2017, 33, 1146.

V. Restelli, M. D. Wang, N. Huzel, M. Ethier, H. Perreault, M. Butler, Biotechnol. Bioeng. 2006, 94, 481.

E. Trummer, K. Fauland, S. Seidinger, K. Schriebl, C. Lattenmayer, R. Kunert, K. Vorauer-Uhl, R. Weik, N. Borth, H. Katinger, D. Müller, Biotechnol. Bioeng. 2006, 94, 1033.

W. Nienow, C. D. Rielly, K. Brosnan, N. Bargh, K. Lee, K. Coopman, C. Hewitt, Biochem. Eng. J. 2013, 76, 25. [37] D. de Wilde, T. Dreher, C. Zahnow, U. Husemann, G. Greller, T. Adams, C. Fenge, BioProcess Int. 2014, 12(8)s. [38] L. K. Ju, G. G. Chase, Bioprocess. Eng. 1992, 8, 49

R. C. Rowland-Jones, F. van den Berg, A. J. Racher, E. B. Martin, C. Jaques, Biotechnol. Prog. 2017, 33, 337.

Zhang, V. L. Tsang, B. Moore, V. Shen, Y. M. Huang, R. Kshirsagar, T. Ryll, Biotechnol. Bioeng. 2015, 112, 2495.

S. Goldrick, K. Lee, C. Spencer, W. Holmes, M. Kuiper, R. Turner, S. S. Farid, Biotechnol. J. 2017, 13, e1700607.

S. R. Velugula-Yellela, A. Williams, N. Trunfio, C. J. Hsu, B. Chavez, S. Yoon, C. Agarabi, Biotechnol. Prog. 2018, 34, 262.

W. Kelly, S. Veigne, X. Li, S. S. Subramanian, Z. Huang, E. Schaefer, Biotechnol. Prog. 2018, 34, 420. [46] C. Grimm, W. Kusser, B. Lee, G. Bremer, A. Bossie, BMC Proc. 2015, 9, P15.

E. B. Moran, S. T. McGowen, J. M. McGuire, J. E. Frankland, I. A. Oyebade, W. Waller, L. C. Archer, L. O. Morris, J. Pandya, S. R. Nathan, L. Smith, M. L. Cadette, J. T. Michalowski, Biotechnol. Bioeng. 2000, 69, 242.

S. Goldrick, W. Holmes, N. J. Bond, G. Lewis, M. Kuiper, R. Turner, S. S. Farid, Biotechnol Bioeng 2017, 114, 2222

M. Sokolov, M. Soos, B. Neunstoecklin, M. Morbidelli, A. Butte, R. Leardi, T. Solacroup, M. Stettler, H. Broly, Biotechnol. Prog. 2015, 31, 1633.

DeCesare, M. Yu, J. Yin, W Zhou, C. Hwang, J. Tengtrakool, K. Konstantinov, Bioprocess Int. 2016, 14, 18.

M. G. Aucoin, M. Perrier, and A. A. Kamen, "Critical assessment of current adeno-associated viral vector production and quantification methods," Biotechnol. Adv., vol. 26, no. 1, pp. 73-88, Jan. 2008.

J. C. M. van der Loo and J. F. Wright, "Progress and challenges in viral vector manufacturing," Hum. Mol. Genet., p. ddv451, Oct. 2015

M. Edelstein, "Gene Therapy Clinical Trials Worldwide provided by the Journal of Gene Medicine." [Online]. Available: http://www.abedia.com/wiley/vectors.php. [Accessed: 07-Oct-2015].

A. M. Mitchell, S. C. Nicolson, J. K. Warischalk, and R. J. Samulski, "AAV's Anatomy: Roadmap for Optimizing Vectors for Translational Success," Curr. Gene Ther., vol. 10, no. 5, pp. 319-340, Oct. 2010.

J. F. Wright, "Adeno-associated viral vector manufacturing: keeping pace with accelerating clinical development," Hum. Gene Ther., vol. 22, no. 8, pp. 913-914, Aug. 2011.

C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. B. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High, and B. Glader, "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B," Blood, vol. 101, no. 8, pp. 2963-2972, Apr. 2003.

A. C. Nathwani, E. G. D. Tuddenham, S. Rangarajan, C. Rosales, J. McIntosh, D. C. Linch, P. Chowdary, A. Riddell, A. J. Pie, C. Harrington, J. O'Beirne, K. Smith, J. Pasi, B. Glader, P. Rustagi, C. Y. C. Ng, M. A. Kay, J. Zhou, Y. Spence, C. L. Morton, J. Allay, J. Coleman, S. Sleep, J. M. Cunningham, D. Srivastava, E. Basner-Tschakarjan, F. Mingozzi, K. A. High, J. T. Gray, U. M. Reiss, A. W. Nienhuis, and A. M. Davidoff, "Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B," N. Engl. J Med., vol. 365, no. 25, pp. 2357-2365, Dec. 2011.

M. A. Kay, C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, V. Arruda, F. Johnson, C. Scallan, E. Skarsgard, A. W. Flake, and K. A. High, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," Nat. Genet., vol. 24, no. 3, pp. 257-26 1, Mar. 2000.

C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H. Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High, and M. A. Kay, "Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response," Nat. Med., vol. 12, no. 3, pp. 342-347, Mar. 2006.

J. W. B. Bainbridge, A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, G. E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S. S. Bhattacharya, A. J. Thrasher, F. W. Fitzke, B. J. Carter, G. S. Rubin, A. T. Moore, and R. R. Ali, "Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis," N. Engl. J Med., vol. 358, no. 21, pp. 2231-2239, May 2008

A. V. Cideciyan, T. S. Aleman, S. L. Boye, S. B. Schwartz, S. Kaushal, A. J. Roman, J. Pang, A. Sumaroka, E. A. M. Windsor, J. M. Wilson, T. R. Flotte, G. A. Fishman, E. Heon, E. M. Stone, B. J. Byrne, S. G. Jacobson, and W. W. Hauswirth, "Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics," Proc. Natl. Acad. Sci., Sep. 2008.

A. M. Maguire, F. Simonelli, E. A. Pierce, E. N. Pugh, F. Mingozzi, J. Bennicelli, S. Banfi, K. A. Marshall, F. Testa, E. M. Surace, S. Rossi, A. Lyubarsky, V. R. Arruda, B. Konkle, E. Stone, J. Sun, J. Jacobs, L. Dell'Osso, R. Hertle, J. Ma, T. M. Redmond, X. Zhu, B. Hauck, 0. Zelenaia, K. S. Shindler, M. G. Maguire, J. F. Wright, N. J. Volpe, J. W. McDonnell, A. Auricchio, K. A. High, and J. Bennett, "Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis," N. Engl. J. Med., vol. 358, no. 21, pp. 2240-2248, May 2008.

W. W. Hauswirth, T. S. Aleman, S. Kaushal, A. V. Cideciyan, S. B. Schwartz, L. Wang, T. J. Conlon, S. L. Boye, T. R. Flotte, B. J. Byrne, and S. G. Jacobson, "Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial," Hum. Gene Ther., vol. 19, no. 10, pp. 979-990, Oct. 2008.

J. J. P. Kastelein, C. J. D. Ross, and M. R. Hayden, "From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world," Hum. Gene Ther., vol. 24, no. 5, pp. 472-478, May 2013. 53 [50]E. S. Stroes, M. C. Nierman, J. J. Meulenberg, R. Franssen, J. Twisk, C. P. Henny, M. M. Maas, A. H. Zwinderman, C. Ross, E. Aronica, K. A. High, M. M. Levi, M. R. Hayden, J. J. Kastelein, and J. A. Kuivenhoven, "Intramuscular administration of AAV 1 -lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients," Arterioscler. Thromb. Vasc. Biol., vol. 28, no. 12, pp. 2303-2304, Dec. 2008.

L. M. Bryant, D. M. Christopher, A. R. Giles, C. Hinderer, J. L. Rodriguez, J. B. Smith, E. A. Traxler, J. Tycko, A. P. Wojno, and J. M. Wilson, "Lessons learned from the clinical development and market authorization of Glybera," Hum. Gene Ther. Clin. Dev., vol. 24, no. 2, pp. 55-64, Jun. 2013.

D. Melchiorri, L. Pani, P. Gasparini, G. Cossu, J. Ancans, J. J. Borg, C. Drai, P. Fiedor, E. Flory, I. Hudson, H. G. Leufkens, J. Mtiller-Berghaus, G. Narayanan, B. Neugebauer, J. Pokrotnieks, J.-L. Robert, T. Salmonson, and C. K. Schneider, "Regulatory evaluation of Glybera in Europe - two committees, one mission," Nat. Rev. Drug Discov., vol. 12, no. 9, pp. 719-719, Sep. 2013.

T. R. Flotte, B. C. Trapnell, M. Humphries, B. Carey, R. Calcedo, F. Rouhani, M. CampbellThompson, A. T. Yachnis, R. A. Sandhaus, N. G. McElvaney, C. Mueller, L. M. Messina, J. M. Wilson, M. Brantly, D. R. Knop, G. Ye, and J. D. Chulay, "Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing aI-antitrypsin: interim results," Hum. Gene Ther., vol. 22, no. 10, pp. 1239-1247, Oct. 2011.

M. L. Brantly, L. T. Spencer, M. Humphries, T. J. Conlon, C. T. Spencer, A. Poirier, W. Garlington, D. Baker, S. Song, K. I. Berns, N. Muzyczka, R. 0. Snyder, B. J. Byrne, and T. R. Flotte, "Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults," Hum. Gene Ther., vol. 17, no. 12, pp. 1177-1186, Dec. 2006.

M. L. Brantly, J. D. Chulay, L. Wang, C. Mueller, M. Humphries, L. T. Spencer, F. Rouhani, T. J. Conlon, R. Calcedo, M. R. Betts, C. Spencer, B. J. Byrne, J. M. Wilson, and T. R. Flotte, "Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV 1 -AAT gene therapy," Proc. Natl. Acad. Sci. U S. A., vol. 106, no. 38, pp. 16363-16368, Sep. 2009.

B. E. Jaski, M. L. Jessup, D. M. Mancini, T. P. Cappola, D. F. Pauly, B. Greenberg, K. Borow, H. Dittrich, K. M. Zsebo, R. J. Hajjar, and Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators, "Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial," J. Card. Fail., vol. 15, no. 3, pp. 171-181, Apr. 2009.

M. Jessup, B. Greenberg, D. Mancini, T. Cappola, D. F. Pauly, B. Jaski, A. Yaroshinsky, K. M. Zsebo, H. Dittrich, R. J. Hajjar, and Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators, "Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure," Circulation, vol. 124, no. 3, pp. 304-313, Jul. 2011.

R. J. Hajjar, K. Zsebo, L. Deckelbaum, C. Thompson, J. Rudy, A. Yaroshinsky, H. Ly, Y. Kawase, K. Wagner, K. Borow, B. Jaski, B. London, B. Greenberg, D. F. Pauly, R. Patten, R. Starling, D. Mancini, and M. Jessup, "Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure," J. Card. Fail., vol. 14, no. 5, pp. 3 55-367, Jun. 2008.

B. Greenberg, A. Yaroshinsky, K. M. Zsebo, J. Butler, G. M. Felker, A. A. Voors, J. J. Rudy, K. Wagner, and R. J. Hajjar, "Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)," JACC Heart Fail., vol. 2, no.1, pp.84-92, Feb.2014.

W. J. Marks, J. L. Ostrem, L. Verhagen, P. A. Starr, P. S. Larson, R. A. Bakay, R. Taylor, D. A. Cahn-Weiner, A. J. Stoessl, C. W. Olanow, and R. T. Bartus, "Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with 54 idiopathic Parkinson's disease: an open-label, phase I trial," Lancet Neurol., vol. 7, no. 5, pp. 400- 408, May 2008.

R. T. Bartus, T. L. Baumann, J. Siffert, C. D. Herzog, R. Alterman, N. Boulis, D. A. Turner, M. Stacy, A. E. Lang, A. M. Lozano, and C. W. Olanow, "Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients," Neurology, vol. 80, no. 18, pp. 1698-1701, Apr. 2013.

J. R. Mendell, L. R. Rodino-Klapac, X. Rosales-Quintero, J. Kota, B. D. Coley, G. Galloway, J. M. Craenen, S. Lewis, V. Malik, C. Shilling, B. J. Byrne, T. Conlon, K. J. Campbell, W. G. Bremer, L. Viollet, C. M. Walker, Z. Sahenk, and K. R. Clark, "Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins," Ann. Neurol., vol. 66, no. 3, pp. 290- 297, Sep. 2009.

D. E. Bowles, S. W. McPhee, C. Li, S. J. Gray, J. J. Samulski, A. S. Camp, J. Li, B. Wang, P. E. Monahan, J. E. Rabinowitz, J. C. Grieger, L. Govindasamy, M. Agbandje-McKenna, X. Xiao, and R. J. Samulski, "Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector," Mol. Ther., vol. 20, no. 2, pp. 443-455, Feb. 2012.

S. Muramatsu, K. Fujimoto, S. Kato, H. Mizukami, S. Asari, K. Ikeguchi, T. Kawakami, M. Urabe, A. Kume, T. Sato, E. Watanabe, K. Ozawa, and I. Nakano, "A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease," Mol. Ther. J. Am. Soc. Gene Ther., vol. 18, no.9, pp.1731-1735, Sep.2010.

W. J. Marks, R. T. Bartus, J. Siffert, C. S. Davis, A. Lozano, N. Boulis, J. Vitek, M. Stacy, D. Turner, L. Verhagen, R. Bakay, R. Watts, B. Guthrie, J. Jankovic, R. Simpson, M. Tagliati, R. Alterman, M. Stern, G. Baltuch, P. A. Starr, P. S. Larson, J. L. Ostrem, J. Nutt, K. Kieburtz, J. H. Kordower, and C. W. Olanow, "Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial," Lancet Neurol., vol. 9, no. 12, pp. 1164-1172, Dec. 2010.

J. L. Eberling, W. J. Jagust, C. W. Christine, P. Starr, P. Larson, K. S. Bankiewicz, and M. J. Aminoff, "Results from a phase I safety trial of hAADC gene therapy for Parkinson disease," Neurology, vol. 70, no. 21, pp. 1980-1983, May 2008.

M. G. Kaplitt, A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, R. J. Bland, D. Young, K. Strybing, D. Eidelberg, and M. J. During, "Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial," Lancet Lond Engl., vol. 369, no. 9579, pp. 2097-2105, Jun. 2007.

C. Janson, S. McPhee, L. Bilaniuk, J. Haselgrove, M. Testaiuti, A. Freese, D.-J. Wang, D. Shera, P. Hurh, J. Rupin, E. Saslow, 0. Goldfarb, M. Goldberg, G. Larijani, W. Sharrar, L. Liouterman, A. Camp, E. Kolodny, J. Samulski, and P. Leone, "Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain," Hum. Gene Ther., vol. 13, no. 11, pp. 1391-1412, Jul. 2002.

S. W. J. McPhee, C. G. Janson, C. Li, R. J. Samulski, A. S. Camp, J. Francis, D. Shera, L. Lioutermann, M. Feely, A. Freese, and P. Leone, "Immune responses to AAV in a phase I study for Canavan disease," J. Gene Med, vol. 8, no. 5, pp. 577-588, May 2006

P. Leone, D. Shera, S. W. J. McPhee, J. S. Francis, E. H. Kolodny, L. T. Bilaniuk, D.-J. Wang, M. Assadi, 0. Goldfarb, H. W. Goldman, A. Freese, D. Young, M. J. During, R. J. Samulski, and C. G. Janson, "Long-term follow-up after gene therapy for canavan disease," Sci. Transl. Med, vol. 4, no. 165, p. 165ra163, Dec. 2012.

D. Sondhi, L. Johnson, K. Purpura, S. Monette, M. M. Souweidane, M. G. Kaplitt, B. Kosofsky, K. Yohay, D. Ballon, J. Dyke, S. M. Kaminksy, N. R. Hackett, and R. G. Crystal, "Long-term expression and safety of administration of AAVrh. 1 OhCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis," Hum. Gene Ther. Methods, vol. 23, no. 5, pp. 324-335, Oct. 2012

S. Worgall, D. Sondhi, N. R. Hackett, B. Kosofsky, M. V. Kekatpure, N. Neyzi, J. P. Dyke, D. Ballon, L. Heier, B. M. Greenwald, P. Christos, M. Mazumdar, M. M. Souweidane, M. G. Kaplitt, and R. G. Crystal, "Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration 55 of a serotype 2 adeno-associated virus expressing CLN2 cDNA," Hum. Gene Ther., vol. 19, no. 5, pp. 463-474, May 2008

K. M. Frank, D. K. Hogarth, J. L. Miller, S. Mandal, P. J. Mease, R. J. Samulski, G. A. Weisgerber, and J. Hart, "Investigation of the Cause of Death in a Gene-Therapy Trial," N. Engl. J Med., vol. 361, no. 2, pp. 161-169, Jul. 2009.

P. J. Mease, K. Hobbs, A. Chalmers, H. El-Gabalawy, A. Bookman, E. Keystone, D. E. Furst, P. Anklesaria, and A. E. Heald, "Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study," Ann. Rheum. Dis., vol. 68, no. 8, pp. 1247-1254, Aug. 2009.

P. J. Mease, N. Wei, E. J. Fudman, A. J. Kivitz, J. Schechtman, R. G. Trapp, K. F. Hobbs, M. Greenwald, A. Hou, S. A. Bookbinder, G. E. Graham, C. W. Wiesenhutter, L. Willis, E. M. Ruderman, J. Z. Forstot, M. J. Maricic, K. H. Dao, C. H. Pritchard, D. N. Fiske, F. X. Burch, H. M. Prupas, P. Anklesaria, and A. E. Heald, "Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study," J. Rheumatol., vol. 37, no. 4, pp. 692-703, Apr. 2010.

A. E. Heald, E. J. Fudman, P. Anklesaria, P. J. Mease, and 13G01 Study Team, "Single-joint outcome measures: preliminary validation of patient-reported outcomes and physical examination," J Rheumatol., vol. 37, no. 5, pp. 1042-1048, May 2010.